About Haihe

Haihe Biopharma focuses on the discovery, development and commercialization of innovative anti-tumor drugs, adheres to the path of independent innovation, and seeks the international development path of original and innovative medicine in China. Haihe Biopharma has a management team led by Ding Jian, the academician of Chinese Academy of Engineering, which pays attention to innovation and has rich experience. It has established a precision medical platform “Guided by Biomarker”, establishes a new drug preclinical evaluation system and clinical research system with advanced technology, standardized operation and in line with international standards, and unit systems covering drug development, CMC research, biomarker discovery and validation, medical strategic planning and clinical research, and builds a new drug R&D system and product management line with superposed advantages and international competitiveness.  

At present, the company’s main research products involve 9 compounds, including 7 compounds in the clinical research stage and 2 compounds in the preclinical research stage.